Marginal zone lymphoma

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

21 regimens on this page 22 variants on this page

Untreated, randomized data

Note: Untreated in this context implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.

BR

back to top

BR: Bendamustine, Rituximab

Regimen

Study	Evidence	Comparator	Efficacy
Flinn et al. 2014 (BRIGHT)	Phase III	R-CHOP;R-CVP	Equivalent RR

• Bendamustine (Treanda) 90 mg/m2 IV over 30 minutes once on days 1 & 2
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

Supportive medications:

• Antiemetics, antipyretics, and antibiotics according to local standard of care
• Prophylactic use of G-CSF allowed according ASCO guidelines (2006)

28-day cycles x up to 8 cycles

References

1. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol PubMed

Chlorambucil (Leukeran)

back to top

Regimen #1

Study	Evidence	Comparator	Efficacy
Leblond et al. 2012 (WM1)	Phase III	Fludarabine	Decreased PFS

• Chlorambucil (Leukeran) 8 mg/m2 (6 mg/m2 per day if older than 75 years old) PO once per day on days 1 to 10

Supportive medications:

• Recommended PCP prophylaxis with one of the following:
  • Trimethoprim/Sulfamethoxazole (Bactrim SS) 1 tablet PO once per day
  • Pentamidine (Nebupent) 300 mg inhaled once per month

28-day cycles x up to 12 cycles

Regimen #2

Study	Evidence	Comparator	Efficacy
Zucca et al. 2013 (IELSG-19)	Phase III	Chlorambucil & Rituximab	Decreased EFS

Induction phase

• Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 42

42-day course of therapy

Stable disease & responders -> consolidation phase

• Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 14

28-day cycles x up to 4 cycles

References

1. Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. link to original article contains verified protocol PubMed
2. Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains verified protocol PubMed

Chlorambucil & Rituximab

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Zucca et al. 2013 (IELSG-19)	Phase III	Chlorambucil	Increased EFS

Induction phase

• Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 42
• Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 22

Stable disease & responders -> consolidation phase

• Chlorambucil (Leukeran) 6 mg/m2 PO once per day on days 1 to 14
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

28-day cycles x up to 4 cycles

References

1. Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains verified protocol PubMed

Fludarabine (Fludara)

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Leblond et al. 2012 (WM1)	Phase III	Chlorambucil	Increased PFS

• Fludarabine (Fludara) 40 mg/m2 (30 mg/m2 per day if older than 75 years old) PO once per day on days 1 to 5

Supportive medications:

• Recommended PCP prophylaxis with one of the following:
  • Trimethoprim/Sulfamethoxazole (Bactrim SS) 1 tablet PO once per day
  • Pentamidine (Nebupent) 300 mg inhaled once per month
• Herpes zoster prophylaxis with one of the following:
  • Valacyclovir (Valtrex) 500 mg PO once per day
  • Acyclovir (Zovirax) 200 to 400 mg PO BID

28-day cycles x up to 6 cycles

References

1. Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7. Epub 2012 Dec 10. link to original article contains verified protocol PubMed

R-CHOP

back to top

R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone

Synonyms: R-CHOP-21, CHOP-R

Structured Concept: C9760 (NCI-T), C0393023 (NCI-MT/UMLS)

• Example orders for R-CHOP in lymphoma

Regimen

Study	Evidence	Comparator	Efficacy
Flinn et al. 2014 (BRIGHT)	Phase III, <20 in this arm	BR;R-CVP	Equivalent RR

• Rituximab (Rituxan) 375 mg/m2 IV once on day 1
• Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
• Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
• Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
• Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5

Supportive medications:

• Antiemetics, antipyretics, and antibiotics per local standard of care
• G-CSF "according to the American Society of Clinical Oncology guidelines"

21-day cycles x up to 8 cycles

References

1. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol PubMed

R-CVP

back to top

R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone

Regimen

Study	Evidence	Comparator	Efficacy
Flinn et al. 2014 (BRIGHT)	Phase III, <20 in this arm	BR;R-CHOP	Equivalent RR

• Rituximab (Rituxan) 375 mg/m2 IV once on day 1
• Cyclophosphamide (Cytoxan) 750 mg/m2 or 1000 mg/m2 IV once on day 1
• Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg per cycle) IV once on day 1
• Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5

Supportive medications:

• Antiemetics, antipyretics, and antibiotics per local standard of care
• G-CSF "according to the American Society of Clinical Oncology guidelines"

21-day cycles x up to 8 cycles

References

1. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944-52. Epub 2014 Mar 3. link to original article contains verified protocol PubMed

Untreated, non-randomized and retrospective data

Note: Untreated in this context implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.

Bortezomib (Velcade)

back to top

Regimen

Study	Evidence
Troch et al. 2009	Phase II

• Bortezomib (Velcade) 1.5 mg/m2 IV bolus once per day on days 1, 4, 8, 11

Supportive medications:

• 5-HT3 antagonist IV immediately before Bortezomib (Velcade)
• 500 mL NS after Bortezomib (Velcade)

21-day cycles x up to 8 cycles

References

1. Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. link to original article contains verified protocol PubMed

Cladribine (Leustatin)

back to top

Study	Evidence
Jäger et al. 2002	Phase II

Regimen

• Cladribine (Leustatin) 0.12 mg/kg IV over 2 hours once on days 1 to 5

Dose reductions:

• "In case of a persisting nadir of the WBCs = 4.0 × 10^9/L (or neutrophils = 1.5 × 10^9/L) and/or the platelets = 100 × 10^9/L, the next treatment cycle was delayed by 1 week until achieving normal values and then treatment was administered at a reduced dose of 0.1 mg/kg body weight."

Supportive medications:

• Not described

28-day cycles x 4 to 6 cycles

References

1. Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. link to original article contains verified protocol PubMed

Cladribine & Rituximab

back to top

Study	Evidence
Troch et al. 2012	Phase II

Regimen

• Cladribine (Leustatin) 0.1 mg/kg SC once per day on days 1 to 4
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

Supportive medications:

• Acetaminophen (Tylenol) 1000 mg PO prior to Rituximab (Rituxan)
• Antihistamine IV prior to Rituximab (Rituxan)
• Either Ondansetron (Zofran) or Tropisetron (Navoban) IV immediately before Cladribine (Leustatin)

21-day cycles up to 6 cycles

References

1. Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. link to original article contains verified protocol PubMed

Fludarabine & Rituximab

back to top

Regimen

Study	Evidence
Salar et al. 2009	Phase II

• Fludarabine (Fludara) 25 mg/m2 IV (or 40 mg/m2 PO) once per day on days 1 to 5
  • Patients with gastric lymphoma received the cycle 1 dose intravenously to guarantee drug absorption
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

Dose reductions:

• • Patients >70 years old could receive Fludarabine (Fludara) at the above dose, but only once per day on days 1 to 3

Supportive medications:

• Trimethoprim/Sulfamethoxazole prophylaxis (dose/schedule not listed) per physician preference
• No routine antiviral prophylaxis or G-CSF use

28-day cycles for 4-6 cycles

References

1. Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. link to orginal article contains verified protocol PubMed

Ibritumomab tiuxetan (Zevalin)

back to top

Regimen

Study	Evidence
Samaniego et al. 2014	Phase II, <20 patients reported

• Rituximab (Rituxan) 250 mg/m2 IV once on day 1, then another single dose on day 8
• Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 14.8 MBq/kg (maximum dose of 1184 MBq) IV once on day 8, given after Rituximab (Rituxan)

Dose reductions:

• Ibritumomab tiuxetan & Yttrium-90 (Zevalin) 11.1 MBq/kg (maximum dose of 1184 MBq) for platelet count between 100 and 149.

One course of therapy

References

1. Samaniego, F., Berkova, Z., Romaguera, J. E., Fowler, N., Fanale, M. A., Pro, B., Shah, J. J., McLaughlin, P., Sehgal, L., Selvaraj, V., Braun, F. K., Mathur, R., Feng, L., Neelapu, S. S. and Kwak, L. W. (2014), 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. British Journal of Haematology. doi: 10.1111/bjh.13021 link to original article contains verified protocol

Lenalidomide (Revlimid)

back to top

Regimen

Study	Evidence
Kiesewetter et al. 2012	Phase II, <20 patients reported

• Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21

Supportive medications:

• Aspirin 100 mg PO once per day

28-day cycle x up to 6 cycles

References

1. Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. doi: 10.3324/haematol.2012.065995. Epub 2012 Aug 16. link to orginal article contains verified protocol PubMed

Lenalidomide & Rituximab

back to top

Regimen

Study	Evidence
Fowler et al. 2014	Phase II

• Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

28-day cycles up to 12 cycles

References

1. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. Epub 2014 Oct 15. link to original article contains protocol PubMed

MCP

back to top

MCP: Mitoxantrone, Chlorambucil, Prednisolone

Regimen

Study	Evidence
Wöhrer et al. 2003	Retrospective

• Mitoxantrone (Novantrone) 8 mg/m2 IV once per day on days 1 & 2
• Chlorambucil (Leukeran) 3 mg/m2 PO TID (written in the reference as "3 x 3 mg/m2"; total dose per day is 9 mg/m2) on days 1 to 5
• Prednisolone (Millipred) 25 mg/m2 PO/IV once per day on days 1 to 5

28-day cycles x up to 8 cycles

References

1. Retrospective: Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. link to orginal article contains verified protocol PubMed

Rituximab (Rituxan)

back to top

Study	Evidence
Conconi et al. 2003	Phase II
Martinelli et al. 2005	Phase II

Regimen

• Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 21

References

1. Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. link to orginal article contains protocol PubMed content property of HemOnc.org
2. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. link to original article contains protocol PubMed

Relapsed/refractory

Bendamustine (Treanda)

back to top

Regimen

Study	Evidence
Kahl et al. 2010	Phase II, <20 patients reported

• Bendamustine (Treanda) 120 mg/m2 IV over 60 to 120 minutes once on days 1 & 2

21-day cycle x 6 to 8 cycles

References

1. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14. link to original article contains verified protocol PubMed

Bortezomib (Velcade)

back to top

Regimen #1

Study	Evidence
Conconi et al. 2011	Phase II

• Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11

Supportive medications:

• No routine growth factors, antibiotic, or antiviral prophylaxis was given

21-day cycles x up to 6 cycles

Regimen #2

Study	Evidence
Troch et al. 2009	Phase II

• Bortezomib (Velcade) 1.5 mg/m2 IV bolus once per day on days 1, 4, 8, 11

Supportive medications:

• 5-HT3 antagonist IV immediately before Bortezomib (Velcade)
• 500 mL NS after Bortezomib (Velcade)

21-day cycles x up to 8 cycles

References

1. Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. link to original article contains verified protocol PubMed
2. Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. link to original article contains verified protocol PubMed

BR

back to top

BR: Bendamustine, Rituximab

Regimen

Study	Evidence
Rummel et al. 2005	Phase II, <20 patients reported

Pre-treatment phase

• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

Cycle 1 is started 7 days after the first dose of rituximab

Main regimen=

• Bendamustine (Treanda) 90 mg/m2 IV over 30 minutes once on days 1 & 2 of cycles 1 to 4
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1 of cycles 1 to 5

28-day cycles x 5 cycles

References

1. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005 May 20;23(15):3383-9. link to original article contains protocol PubMed

Cladribine & Rituximab

back to top

Regimen

Study	Evidence
Troch et al. 2012	Phase II, <20 patients reported

• Cladribine (Leustatin) 0.1 mg/kg SC once per day on days 1 to 4
• Rituximab (Rituxan) 375 mg/m2 IV once on day 1

Supportive medications:

• Acetaminophen (Tylenol) 1000 mg PO prior to Rituximab (Rituxan)
• Antihistamine IV prior to Rituximab (Rituxan)
• Either Ondansetron (Zofran) or Tropisetron (Navoban) IV immediately before Cladribine (Leustatin)

21-day cycles up to 6 cycles

References

1. Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. link to original article contains verified protocol PubMed

Idelalisib (Zydelig)

back to top

Regimen,

Study	Evidence
Gopal et al. 2014 (DELTA)	Phase II, <20 patients in this subgroup

• Idelalisib (Zydelig) 150 mg PO BID

Continued until progression, death, or unacceptable toxicity

References

1. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med. 2014 Jan 22. link to original article contains verified protocol PubMed
   1. Update: Abstract: Ajay K. Gopal, MD, Brad S. Kahl, MD, Sven de Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Christopher R. Flowers, MD, Peter Martin, MD, Andreas Viardot, MD, Kristie A. Blum, MD, Andre Goy, MD, Andrew Davies, BM PhD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD, PhD, Leanne M. Holes, Bess Sorensen, PhD, Wayne R. Godfrey, MD and Gilles Andre Salles, MD, PhD. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). ASH Annual Meeting 2014, Abstract 1708 link to abstract

Lenalidomide (Revlimid)

back to top

Regimen

Study	Evidence
Kiesewetter et al. 2012	Phase II, <20 patients reported

• Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21

Supportive medications:

• Aspirin 100 mg PO once per day

28-day cycle x up to 6 cycles

References

1. Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. doi: 10.3324/haematol.2012.065995. Epub 2012 Aug 16. link to orginal article contains verified protocol PubMed

Rituximab (Rituxan)

back to top

Regimen

Study	Evidence
Conconi et al. 2003	Phase II
Martinelli et al. 2005	Phase II

• Rituximab (Rituxan) 375 mg/m2 IV once per day on days 1, 8, 15, 21

References

1. Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. link to orginal article contains protocol PubMed
2. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. link to original article contains protocol PubMed